COVID-19 Access Industrial Policy Regulatory and legal framework Falsified medicines Environment Antimicrobial resistance Medicine shortages

 

COVID-19

To ensure manufacturing and supplying, day and night our members are continuously assessing portfolios, forecast, manufacture and supply to best meet the increasing demands posed by COVID19.

We are working closely with government and policy makers both at EU and national level so that we do all we can to maintain the development, production, supply and distribution of high-quality medicines during the pandemic

 

Key documents


SUPPLY


TREATMENT


TRANSPORT


REGULATORY


WORK FORCE

[1] The Parliament Magazine. 2015. Available at:- https://www.theparliamentmagazine.eu/articles/opinion/many-patients-europe-have-limited-or-no-access-treatment

[2] Eurostat Population Statistics

[3] OECD, Fiscal Sustainability of Health Systems: Bridging Health and Finance Perspectives. 2015.

[4] SFK (Foundation for Pharmaceutical Statistics), Pharmaceutisch Weekblad. 2014.

[5] APM Health 2015. Available at: http://www.apmhealtheurope.com/home.php.

[6] QuintilesIMS Health. An International Comparison of Best Practice Approaches to Drug Shortages. 2015.